Here's a link to an article from Medscape Current and New Approaches in MS Therapies that discusses several of the oral therapies in the pipeline (and others).
You may have to register first, but it's free. It's program 7687.
I followed up on my previous post with an email to Novartis to find out if the results from the completed Phase III trial in Renal transplant patients would result in FTY720 being commercially available before it is available after the current Phase III trial in MS. Below is the response I got back.
Renal transplantation Phase III results indicated that FTY720 in combination with cyclosporine provides no benefit over the current standard of care. Therefore, all clinical trials have been stopped. FTY720 is currently in Phase III trials to test is safety and efficacy in patients with relapsing-remitting multiple sclerosis.
Please let me know if you have any additional questions.
Julie Morrow, PhD
Global PR Manager, Neuroscience
- Similar Topics
- Last post